Asthma phenotypes: the evolution from clinical to molecular approaches

Although asthma has been considered as a single disease for years, recent studies have increasingly focused on its heterogeneity. The characterization of this heterogeneity has promoted the concept that asthma consists of multiple phenotypes or consistent groupings of characteristics. Asthma phenotypes were initially focused on combinations of clinical characteristics, but they are now evolving to link biology to phenotype, often through a statistically based process. Ongoing studies of large-scale, molecularly and genetically focused and extensively clinically characterized cohorts of asthma should enhance our ability to molecularly understand these phenotypes and lead to more targeted and personalized approaches to asthma therapy.

[1]  F. M. Rackemann.  A working classification of asthma. , 1947, The American journal of medicine.

[2]  M. Samter,et al.  Concerning the nature of intolerance to aspirin. , 1967, The Journal of allergy.

[3]  S. Peters,et al.  An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils. , 1989, The Journal of pharmacology and experimental therapeutics.

[4]  P. Howarth,et al.  Quantitation of mast cells and eosinophils in the bronchial mucosa of symptomatic atopic asthmatics and healthy control subjects using immunohistochemistry. , 1991, The American review of respiratory disease.

[5]  A. Ford-hutchinson,et al.  Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. , 1991, The American review of respiratory disease.

[6]  G. Delespesse,et al.  Glucocorticoids suppress the production of interleukin 4 by human lymphocytes , 1991, European journal of immunology.

[7]  S. Holgate,et al.  Role of leukotrienes in exercise-induced asthma. Inhibitory effect of ICI 204219, a potent leukotriene D4 receptor antagonist. , 1992, The American review of respiratory disease.

[8]  P. Leder,et al.  An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. , 1992, Science.

[9]  M. Brown,et al.  Immunosuppression by glucocorticoids: inhibition of production of multiple lymphokines by in vivo administration of dexamethasone. , 1993, Cellular immunology.

[10]  B. Spiegelman,et al.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. , 1993, Science.

[11]  R. Schleimer,et al.  The effects of glucocorticoids on human eosinophils. , 1994, The Journal of allergy and clinical immunology.

[12]  T. Kato,et al.  Inhibition by dexamethasone of human neutrophil apoptosis in vitro. , 1995, Natural immunity.

[13]  A. J. Wilson,et al.  Eosinophil apoptosis and the resolution of airway inflammation in asthma. , 1996, American journal of respiratory and critical care medicine.

[14]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[15]  502 High affinity IgE receptor (FcεRI)-bearing cells in bronchial biopsies from atopic and non-atopic asthma , 1996 .

[16]  Nitric oxide in exhaled air is a new marker of airway inflammation. , 1996, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[17]  S. Durham,et al.  IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against "intrinsic" asthma being a distinct immunopathologic entity. , 1996, American journal of respiratory and critical care medicine.

[18]  P. Howarth,et al.  The effect of treatment with oral corticosteroids on asthma symptoms and airway inflammation. , 1997, American journal of respiratory and critical care medicine.

[19]  M. Sanak,et al.  Leukotriene C 4 synthase promoter polymorphism and risk of aspirin-induced asthma , 1997, The Lancet.

[20]  H. Boushey,et al.  The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. , 1997, American journal of respiratory and critical care medicine.

[21]  C. Bachert,et al.  IL-5 synthesis is upregulated in human nasal polyp tissue. , 1997, The Journal of allergy and clinical immunology.

[22]  S. Wenzel,et al.  Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. , 1997, American journal of respiratory and critical care medicine.

[23]  T. Reiss,et al.  Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. , 1997, Thorax.

[24]  S. Durham,et al.  Increase in exhaled nitric oxide levels in patients with difficult asthma and correlation with symptoms and disease severity despite treatment with oral and inhaled corticosteroids , 1998, Thorax.

[25]  J. Bousquet,et al.  Increased Levels of Elastase and α1-Antitrypsin in Sputum of Asthmatic Patients , 1998 .

[26]  L. Dubé,et al.  Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. , 1998, American journal of respiratory and critical care medicine.

[27]  T. Haahtela,et al.  Asthma and increased bronchial responsiveness in elite athletes: atopy and sport event as risk factors. , 1998, The Journal of allergy and clinical immunology.

[28]  D B Corry,et al.  Requirement for IL-13 independently of IL-4 in experimental asthma. , 1998, Science.

[29]  M. Lane,et al.  Leptin regulates proinflammatory immune responses. , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[30]  D D Donaldson,et al.  Interleukin-13: central mediator of allergic asthma , 1998 .

[31]  J. Brieva,et al.  T lymphocytes that infiltrate nasal polyps have a specialized phenotype and produce a mixed TH1/TH2 pattern of cytokines. , 1998, The Journal of allergy and clinical immunology.

[32]  S. Holgate,et al.  Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. , 1998, The Journal of clinical investigation.

[33]  L. Borish,et al.  Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. , 1999, American journal of respiratory and critical care medicine.

[34]  S. Wenzel,et al.  Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. , 1999, American journal of respiratory and critical care medicine.

[35]  I. Pavord,et al.  Prednisone-dependent asthma: inflammatory indices in induced sputum. , 1999, The European respiratory journal.

[36]  K. Chung,et al.  Neutrophilic inflammation in severe persistent asthma. , 1999, American journal of respiratory and critical care medicine.

[37]  A R Zinsmeister,et al.  Risk factors associated with symptoms of gastroesophageal reflux. , 1999, The American journal of medicine.

[38]  D. H. Zhang,et al.  Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. , 1999, Immunity.

[39]  L. Bjermer,et al.  Evidence of airway inflammation and remodeling in ski athletes with and without bronchial hyperresponsiveness to methacholine. , 2000, American journal of respiratory and critical care medicine.

[40]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[41]  P. O'Byrne,et al.  Induced sputum cell counts in healthy adults. , 2000, American journal of respiratory and critical care medicine.

[42]  J. Douwes,et al.  Is allergen exposure the major primary cause of asthma? , 2000, Thorax.

[43]  A. Spanevello,et al.  Induced sputum cellularity. Reference values and distribution in normal volunteers. , 2000, American Journal of Respiratory and Critical Care Medicine.

[44]  R. Townley,et al.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.

[45]  M. Segal,et al.  Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. , 2001, The Journal of allergy and clinical immunology.

[46]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[47]  I. Pavord,et al.  Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids , 2002, Thorax.

[48]  S. Wenzel,et al.  Expression and activation of 15‐lipoxygenase pathway in severe asthma: relationship to eosinophilic phenotype and collagen deposition , 2002, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[49]  D. Sin,et al.  Obesity is a risk factor for dyspnea but not for airflow obstruction. , 2002, Archives of internal medicine.

[50]  P. Phelan,et al.  The Melbourne Asthma Study: 1964-1999. , 2002, The Journal of allergy and clinical immunology.

[51]  R. Pauwels,et al.  Improvement of aspirin-intolerant asthma by montelukast, a leukotriene antagonist: a randomized, double-blind, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[52]  I. Pavord,et al.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.

[53]  P. Gibson,et al.  Relationship between induced sputum eosinophils and the clinical pattern of childhood asthma , 2003, Thorax.

[54]  K. Hveem,et al.  Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. , 2003, JAMA.

[55]  L. Boulet,et al.  Airway remodeling-associated mediators in moderate to severe asthma: effect of steroids on TGF-beta, IL-11, IL-17, and type I and type III collagen expression. , 2003, The Journal of allergy and clinical immunology.

[56]  A. Zwinderman,et al.  "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. , 2004, American journal of respiratory and critical care medicine.

[57]  S. Wenzel,et al.  Distinguishing severe asthma phenotypes: role of age at onset and eosinophilic inflammation. , 2004, The Journal of allergy and clinical immunology.

[58]  H. Shin,et al.  Leukotriene-related gene polymorphisms in ASA-intolerant asthma: an association with a haplotype of 5-lipoxygenase , 2004, Human Genetics.

[59]  D. Postma,et al.  A disintegrin and metalloprotease 33 polymorphisms and lung function decline in the general population. , 2005 .

[60]  M. Zeitz,et al.  Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. , 2005, Gastroenterology.

[61]  W. Henderson,et al.  Airway immunopathology of asthma with exercise-induced bronchoconstriction. , 2005, The Journal of allergy and clinical immunology.

[62]  R. Scott,et al.  Differential proteolytic enzyme activity in eosinophilic and neutrophilic asthma. , 2005, American journal of respiratory and critical care medicine.

[63]  C. Brightling,et al.  The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. , 2005, American journal of respiratory and critical care medicine.

[64]  S. Wenzel.  Asthma: defining of the persistent adult phenotypes , 2006, The Lancet.

[65]  Cleo C. van Diemen,et al.  A Disintegrin and Metalloprotease 33 polymorphisms and lung function decline in the general population , 2006, European Respiratory Review.

[66]  J. Banks,et al.  Characterization of Within-Subject Responses to Fluticasone and Montelukast in Childhood Asthma , 2006, Pediatrics.

[67]  S. Erzurum,et al.  Features of severe asthma in school-age children: Atopy and increased exhaled nitric oxide. , 2006, The Journal of allergy and clinical immunology.

[68]  L. Boulet,et al.  Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations , 2006, European Respiratory Journal.

[69]  J. Kelso.  Inflammatory Basis of Exercise-Induced Bronchoconstriction , 2006, Pediatrics.

[70]  I. Pavord,et al.  Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma , 2007, Thorax.

[71]  M. Rojas,et al.  Paying attention to neglected diseases. , 2004, Environmental health perspectives.

[72]  W. Busse,et al.  A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.

[73]  H. Young,et al.  Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13. , 2007, American journal of respiratory and critical care medicine.

[74]  S. Willsie.  Influence of body mass index on the response to asthma controller agents , 2007 .

[75]  Paul E Moore,et al.  Bronchiolitis to asthma: a review and call for studies of gene-virus interactions in asthma causation. , 2007, American journal of respiratory and critical care medicine.

[76]  S. Wenzel,et al.  Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies , 2007, The Lancet.

[77]  C. Lemière,et al.  Differences in airway cytokine profile in severe asthma compared to moderate asthma. , 2008, Chest.

[78]  G. Anderson,et al.  Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneous disease , 2008, The Lancet.

[79]  Mike Thomas,et al.  Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.

[80]  R. Scott,et al.  Clarithromycin targets neutrophilic airway inflammation in refractory asthma. , 2008, American journal of respiratory and critical care medicine.

[81]  J. Alcorn,et al.  TH17 Cells Mediate Steroid-Resistant Airway Inflammation and Airway Hyperresponsiveness in Mice1 , 2008, The Journal of Immunology.

[82]  R. Metson,et al.  Gene Expression Profiling of Nasal Polyps Associated With Chronic Sinusitis and Aspirin‐Sensitive Asthma , 2008, The Laryngoscope.

[83]  M. Humbert,et al.  Add‐on omalizumab improves day‐to‐day symptoms in inadequately controlled severe persistent allergic asthma , 2008, Allergy.

[84]  S. Wenzel,et al.  IL‐13 induced increases in nitrite levels are primarily driven by increases in inducible nitric oxide synthase as compared with effects on arginases in human primary bronchial epithelial cells , 2008, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[85]  I. Pavord,et al.  Increased sputum and bronchial biopsy IL-13 expression in severe asthma. , 2008, The Journal of allergy and clinical immunology.

[86]  P. Boschetto,et al.  Mechanisms of occupational asthma. , 2009, The Journal of allergy and clinical immunology.

[87]  Parameswaran Nair,et al.  Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.

[88]  Barmak Modrek,et al.  T-helper type 2-driven inflammation defines major subphenotypes of asthma. , 2009, American journal of respiratory and critical care medicine.

[89]  I. Adcock,et al.  Suppression of GATA-3 Nuclear Import and Phosphorylation: A Novel Mechanism of Corticosteroid Action in Allergic Disease , 2009, PLoS medicine.

[90]  Cecilia Kim,et al.  Chromosome 17q21 gene variants are associated with asthma and exacerbations but not atopy in early childhood. , 2009, American journal of respiratory and critical care medicine.

[91]  E. Hoffman,et al.  A multivariate analysis of risk factors for the air-trapping asthmatic phenotype as measured by quantitative CT analysis. , 2009, Chest.

[92]  J. Skripak.  Chromosome 17q21 Gene Variants Are Associated With Asthma and Exacerbations But Not Atopy in Early Childhood , 2009, Pediatrics.

[93]  J. Cowan,et al.  Effects of steroid therapy on inflammatory cell subtypes in asthma , 2009, Thorax.

[94]  D. Postma,et al.  The role of female sex hormones in the development and severity of allergic and non‐allergic asthma , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[95]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[96]  I. Pavord,et al.  Qualitative analysis of high-resolution CT scans in severe asthma. , 2009, Chest.

[97]  Judith L. Black,et al.  Intrinsic asthma: is it intrinsic to the smooth muscle? , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[98]  N. Thomson,et al.  Asthma in smokers: challenges and opportunities , 2009, Current opinion in pulmonary medicine.

[99]  K. Rabe,et al.  Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. , 2009, The Journal of allergy and clinical immunology.

[100]  M. Wills-Karp,et al.  Complement-mediated Regulation Of The IL-17A Axis Is A Central Genetic Determinant Of The Severity Of Experimental Allergic Asthma , 2010, ATS 2010.

[101]  Deborah A Meyers,et al.  Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. , 2010, The Journal of allergy and clinical immunology.

[102]  M. Kraft,et al.  Pulmonary Physiology and Pathophysiology of Obesity Does obesity produce a distinct asthma phenotype ? , 2010 .

[103]  M. Solon,et al.  Accumulation of intraepithelial mast cells with a unique protease phenotype in T(H)2-high asthma. , 2010, The Journal of allergy and clinical immunology.

[104]  Jennifer R. Clark,et al.  Complement-mediated regulation of the interleukin 17A axis is a central genetic determinant of the severity of experimental allergic asthma , 2010, Nature Immunology.

[105]  Sally E Wenzel,et al.  A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. , 2010, American journal of respiratory and critical care medicine.

[106]  D. Curran‐Everett,et al.  Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. , 2010, American journal of respiratory and critical care medicine.

[107]  W. Busse,et al.  Racial differences in biologic predictors of severe asthma: Data from the Severe Asthma Research Program. , 2010, The Journal of allergy and clinical immunology.

[108]  J. Gern.  The ABCs of Rhinoviruses, Wheezing, and Asthma , 2010, Journal of Virology.

[109]  K. Bønnelykke,et al.  Long-term studies of the natural history of asthma in childhood. , 2010, The Journal of allergy and clinical immunology.

[110]  E. White,et al.  Coevolution of TH1, TH2, and TH17 Responses during Repeated Pulmonary Exposure to Aspergillus fumigatus Conidia , 2010, Infection and Immunity.

[111]  Florence Demenais,et al.  A large-scale, consortium-based genomewide association study of asthma. , 2010, The New England journal of medicine.

[112]  C. Brightling,et al.  Expression of the T Helper 17-Associated Cytokines IL-17A and IL-17F in Asthma and COPD , 2010, Chest.

[113]  D. Umetsu,et al.  The many paths to asthma: phenotype shaped by innate and adaptive immunity , 2010, Nature Immunology.

[114]  IL-4 receptor α polymorphisms are predictors of a pharmacogenetic response to a novel IL-4/IL-13 antagonist. , 2010, The Journal of allergy and clinical immunology.

[115]  W. Henderson,et al.  Transglutaminase 2, a Novel Regulator of Eicosanoid Production in Asthma Revealed by Genome-Wide Expression Profiling of Distinct Asthma Phenotypes , 2010, PloS one.

[116]  L. Boulet,et al.  A comparison of obese and nonobese people with asthma: exploring an asthma-obesity interaction. , 2010, Chest.

[117]  L. Boulet,et al.  Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. , 2011, American journal of respiratory and critical care medicine.

[118]  Mario Castro,et al.  Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. , 2011, The Journal of allergy and clinical immunology.

[119]  C. Akdis,et al.  IL‐33 links tissue cells, dendritic cells and Th2 cell development in a mouse model of asthma , 2011, European journal of immunology.

[120]  A. Carlin,et al.  The Effects of Bariatric Surgery on Asthma Severity , 2011, Obesity surgery.

[121]  R. Pratley,et al.  Effects of obesity and bariatric surgery on airway hyperresponsiveness, asthma control, and inflammation. , 2011, The Journal of allergy and clinical immunology.

[122]  W. Busse,et al.  Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy , 2011, Annals of Internal Medicine.

[123]  S. Akira,et al.  TNF-α from inflammatory dendritic cells (DCs) regulates lung IL-17A/IL-5 levels and neutrophilia versus eosinophilia during persistent fungal infection , 2011, Proceedings of the National Academy of Sciences.

[124]  P. Sly,et al.  Interaction between adaptive and innate immune pathways in the pathogenesis of atopic asthma: operation of a lung/bone marrow axis. , 2011, Chest.

[125]  S. Mosesova,et al.  Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. , 2011, The Journal of allergy and clinical immunology.

[126]  P. Gourdy,et al.  A natural protective function of invariant NKT cells in a mouse model of innate‐cell‐driven lung inflammation , 2011, European journal of immunology.

[127]  W. White,et al.  Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma , 2011, BMC pulmonary medicine.

[128]  Predictive and Pharmacodynamic Biomarkers of Interleukin-13 Blockade: Effect of Lebrikizumab on Late Phase Asthmatic Response to Allergen Challenge , 2011 .

[129]  Obesity And Asthma, An Association Modified By Age Of Asthma Onset , 2011, ATS 2011.

[130]  Adnan Custovic,et al.  Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. , 2011, The Journal of allergy and clinical immunology.

[131]  Margaret W Leigh,et al.  An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. , 2011, American journal of respiratory and critical care medicine.

[132]  G. Giles,et al.  Childhood eczema and rhinitis predict atopic but not nonatopic adult asthma: a prospective cohort study over 4 decades. , 2011, The Journal of allergy and clinical immunology.

[133]  Alexander A. Morgan,et al.  Identification of an IFN-γ/mast cell axis in a mouse model of chronic asthma. , 2011, The Journal of clinical investigation.

[134]  D. Jarvis,et al.  Identifying adult asthma phenotypes using a clustering approach , 2011, European Respiratory Journal.

[135]  Jodie L Simpson,et al.  Transcriptional phenotypes of asthma defined by gene expression profiling of induced sputum samples. , 2011, The Journal of allergy and clinical immunology.

[136]  E. Bleecker,et al.  A Phase 2b Study Of Inhaled Pitrakinra, An IL-4/IL-13 Antagonist, Successfully Identified Responder Subpopulations Of Patients With Uncontrolled Asthma , 2011, ATS 2011.

[137]  P. Gergen,et al.  Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. , 2011, The New England journal of medicine.

[138]  Lee， Jk,et al.  Lebrikizumab treatment in adults with asthma. , 2011 .

[139]  W. Busse,et al.  Predictive Model Of Severe Atopic Asthma Phenotypes Using Interleukin 4/13 Pathway Polymorphisms , 2011, ATS 2011.

[140]  W. Busse,et al.  Importance of hedgehog interacting protein and other lung function genes in asthma. , 2011, The Journal of allergy and clinical immunology.

[141]  S. Wenzel,et al.  Nitric oxide and related enzymes in asthma: relation to severity, enzyme function and inflammation , 2012, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[142]  J. Stockman,et al.  A Large-Scale, Consortium-Based Genomewide Association Study of Asthma , 2012 .